CoChat

Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years

Spielberg, Leigh, Leys, Anita · 2010 · Graefe's Archive for Clinical and Experimental Ophthalmology

The DOI matches its Crossref record; the references it cites are not checked yet.

Abstract

Background The combination of verteporfin photodynamic therapy (PDT) and anti-angiogenics has been shown to be safe and efficacious in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). The purpose of this study is to demonstrate long-term prevention of vision loss and improvement in best-corrected visual acuity (BCVA) after treatment with one-time reduced-fluence-rate PDT followed by administration of ranibizumab on a variable dosing regimen over 24 months in patients with neovascular AMD. Secondary outcome measures included the change in central macular thickness (CMT), reinjection frequency, and safety. Methods This prospective, nonrandomized, open-label, single-center study enrolled 27 consecutive patients (27 eyes) presenting at the Leuven University Eye Hospital with previously untreated, active neovascular AMD between September 2006 and January 2007. All patients were treated with one-time, reduced-fluence-rate verteporfin PDT, followed by intravitreal ranibizumab 0.5 mg on the same day. A second and third ranibizumab injection were given at weeks 4 and 8, respectively, after which patients were followed up monthly for 24 months. Additional treatment with ranibizumab was administered to eyes with active neovascularization as indicated clinically and on imaging studies. Retreatment was based on the following criteria: (1) presence of subretinal fluid (SRF), intraretinal edema or sub-retinal pigment epithelial fluid,…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00417-009-1256-6

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

The citation lists are queued

They are fetched later and appear here then.

References 41 · Cited by 31

Metadata

Authors
Spielberg, L., & Leys, A.
Affiliations
Universitair Ziekenhuis Leuven (BE)
Corresponding author
Spielberg, Leigh
Venue
Graefe's Archive for Clinical and Experimental Ophthalmology
Published
2010-03-04
Volume
248
Issue
7
Pages
943-956
ISSN
  • 0721-832X (ISSN-L)
  • 1435-702X
OpenAlex
W2064939547
Cited by
31
References
41
Citations by year
2024: 2 · 2022: 1 · 2021: 2 · 2020: 2 · 2018: 1 · 2016: 3 · 2015: 4 · 2014: 4 · 2013: 3 · 2012: 6
FWCI
4.20
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Graefe s Archive for Clinical and Experimental Ophthalmology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Keywords
neovascular age-related macular degeneration, choroidal neovascularization, ranibizumab, verteporfin photodynamic therapy, anti-VEGF therapy, best-corrected visual acuity, central macular thickness, occult CNV, subretinal fluid
MeSH terms
Ranibizumab, Verteporfin, Aged, Aged, 80 and over, Antibodies, Monoclonal, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Macular Degeneration, Male, Middle Aged, Photochemotherapy, Porphyrins, Prospective Studies, Time Factors, Visual Acuity, Treatment Outcome, Photosensitizing Agents, Angiogenesis Inhibitors, Tomography, Optical Coherence, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. https://app.cochat.ai/papers/10.1007/s00417-009-1256-6
The paper
Spielberg, L., & Leys, A. (2010). Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-009-1256-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.